Moderna, Inc.

Biotechnology and mRNA TherapeuticsFounded 2010- Updated July 2025

Last reviewed: July 2025

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.

CorpDigest

Search brand historiesSearchK Contact

Moderna, Inc.

Biotechnology and mRNA TherapeuticsFounded 2010- Updated July 2025

Reviewed by Swet Parvadiya

Last reviewed: July 2025

Independent Editorial Analysis

Last Reviewed: July 2025

Last reviewed: July 2025 · 16 historical events · Editorial analysis

Moderna, Inc. Revenue, History, and Strategy

Last Updated: July 2025

Research depth: 16 milestones · 12 FAQs · Updated July 2025

Annual Revenue$1.9B

Founded2010

IndustryBiotechnology and mRNA Therapeutics

By Swet ParvadiyaLast reviewed: July 15, 2025

Profile last reviewed: July 15, 2025Reviewed by Swet Parvadiya Data sources: annual reports, SEC filings, methodology

Industry:Biotechnology and mRNA Therapeutics

Last reviewed: July 15, 2025

Editorial Perspective

Moderna's 2025 annual report discloses that the company has reduced its annual operating expenses by $2.2 billion, exceeding its original cost-reduction target by more than $200 million, while still maintaining a pipeline of more than 45 programs and three approved products. This cost discipline, achieved through manufacturing rightsizing, R&D portfolio prioritization, and workforce reduction, may be the most critical factor determining whether Moderna survives its transition from pandemic windfall to sustainable biotechnology enterprise. The company's 2025 annual report also discloses that Moderna has filed more than 1,400 patents and patent applications, protecting its intellectual property across mRNA modification, lipid nanoparticle formulation, and manufacturing processes. This patent portfolio, while valuable, also creates licensing obligations and potential litigation risks that could affect future profitability. The combination of the patent portfolio, the declining cash position, and the ambitious pipeline targets creates a high-stakes environment where intellectual property strategy will be as important as clinical execution.

Reviewed by Swet Parvadiya, Founder & EditorLast reviewed: 2026

In-Depth Analysis

4,309 words · 22 min read

Moderna, Inc. generated $1.944 billion in Total Revenue in fiscal year 2025, a 40% decrease from 2024, reflecting the continued collapse of COVID-19 vaccine demand from pandemic peaks to endemic seasonal levels. The company, which saw its market capitalization exceed $180 billion in 2021 when Spikevax generated $17.7 billion in annual revenue, now trades at approximately $18.8 billion as it navigates a dramatic transformation from pandemic contractor to diversified biotechnology enterprise. Moderna has three approved mRNA products, Spikevax for COVID-19, mNEXSPIKE as a next-generation COVID vaccine, and mRESVIA for RSV prevention, alongside a pipeline of more than 45 programs spanning respiratory vaccines, latent viruses, rare diseases, and immuno-oncology. Under CEO Stéphane Bancel, the company has reduced operating expenses by $2.2 billion in 2025, exceeding targets, and aims to achieve cash break-even by 2028. The company ended 2025 with approximately $6 billion in cash and investments, providing roughly two years of runway at current burn rates.

Moderna: Key Facts

Founded: September 2010 by Derrick Rossi, Robert Langer, Noubar Afeyan, and Kenneth Chien in Cambridge, Massachusetts
Headquarters: Cambridge, Massachusetts
CEO: Stéphane Bancel, appointed founding CEO in 2011
Employees: Approximately 4,800 across 18 countries (down from 5,800 in 2024)
FY2025 Revenue: $1.944 billion, down 40% from 2024
Market Cap: Approximately $18.8 billion (down from $180+ billion peak in 2021)
Primary Products: Spikevax (COVID-19), mNEXSPIKE (next-gen COVID), mRESVIA (RSV)
Pipeline: 45+ programs including flu vaccine, norovirus vaccine, and personalized cancer vaccines
Cash Position: Approximately $6 billion at year-end 2025
Net Loss: $2.822 billion in FY2025, a 21% improvement from 2024
Listing: Nasdaq Global Select Market (MRNA)

How Does Moderna Make Money?

Moderna makes money through three revenue streams that generated $1.944 billion in 2025. Net Product Sales of mRNA vaccines produced $1.818 billion, representing 94% of Total Revenue, with U.S. sales of $1.2 billion and international sales of $745 million. The company sells Spikevax, mNEXSPIKE, and mRESVIA to government procurement agencies, retail pharmacies, and international distributors. Collaboration Revenue from partnerships with Merck and others contributed approximately $60 million, down as the company focuses on proprietary products. Other Revenue of $126 million includes grant funding and stand-ready manufacturing agreements. The company's revenue is highly seasonal, with 40-50% of annual sales occurring in the third quarter and the balance in the fourth quarter, reflecting fall vaccination patterns. The cost of sales was $868 million in 2025, or 48% of net product sales, including $291 million in inventory write-downs and $88 million in third-party royalties. The gross margin remains negative when including capacity underutilization and wind-down costs, a structural challenge that the cost-reduction program aims to address.

Who Founded Moderna and When?

Moderna was founded in September 2010 by Derrick Rossi, a Harvard stem cell biologist who discovered that modified mRNA could reprogram adult cells; Robert Langer, an MIT professor and drug delivery pioneer; Noubar Afeyan, CEO of Flagship Pioneering; and Kenneth Chien, a Harvard cardiovascular scientist. The company was incubated by Flagship Pioneering with seed funding and scientific infrastructure. The name derives from modified RNA. CEO Stéphane Bancel joined as founding CEO in 2011, bringing pharmaceutical commercial experience from bioMérieux and Eli Lilly. The company's founding vision was to create a digital biotech platform using mRNA to instruct human cells to produce therapeutic proteins. Moderna operated in stealth mode for two years before emerging publicly in 2012 with a $40 million Series A. The early years were characterized by skepticism from the scientific community, as mRNA had never been successfully developed into an approved medicine, but the company's rapid platform development and strategic partnerships with AstraZeneca and Merck validated its potential before the COVID-19 pandemic transformed its fortunes.

What Is Moderna's Competitive Advantage?

Moderna's competitive advantage is its proprietary mRNA platform technology, which demonstrated the ability to develop Spikevax from sequence selection to FDA authorization in 11 months, shattering all vaccine development records. The platform's cell-free manufacturing process provides flexibility that traditional cell-culture vaccine manufacturing cannot match, enabling rapid strain updates for seasonal vaccines. The lipid nanoparticle delivery technology, developed with partners including Acuitas and Arbutus, protects mRNA from degradation and facilitates cellular uptake, creating a formulation moat. The manufacturing infrastructure in Massachusetts, New Hampshire, the UK, Canada, and Australia provides global production capacity that can be repurposed across different mRNA products. In oncology, the personalized cancer vaccine approach using patient-specific neoantigens represents a differentiated strategy, with Phase 2 data showing a 44% reduction in recurrence risk when combined with Merck's Keytruda. The $6 billion cash position provides funding advantage over smaller biotechnology competitors, and the scientific talent base of more than 3,000 researchers represents intellectual capital that is difficult to replicate.

How Has Moderna's Revenue Grown Over Time?

Moderna's revenue trajectory is one of the most dramatic in pharmaceutical history. The company reported $0 in product revenue through 2019, then generated $0.8 billion in 2020 from government advance purchase agreements for Spikevax development. Revenue exploded to $17.7 billion in 2021 as Spikevax became one of the best-selling pharmaceutical products in history. The 2022 result of $18.4 billion represented the peak, as government procurement transitioned to commercial sales. Revenue then collapsed to $6.8 billion in 2023, a 63% decline, as the market normalized. The 2024 result of $3.2 billion, a further 53% decline, reflected the transition to endemic seasonal demand. The 2025 result of $1.9 billion, a 40% decline, shows the market stabilizing at a lower level but still contracting. The 2026 guidance projects up to 10% growth, to approximately $2.1 billion, assuming continued cost discipline and successful product launches. This trajectory demonstrates the volatility of pandemic-dependent revenue and the challenge of building sustainable commercial franchises in seasonal vaccine markets.

Moderna Business Model Explained

Moderna's business model is built on platform biotechnology, using mRNA to encode therapeutic proteins that the human body produces naturally. The company invests $3.1 billion annually in R&D, down from $4.5 billion in 2024, to discover and develop mRNA medicines across infectious diseases, cancer, and rare diseases. Successful vaccines are manufactured in a global network of facilities in Massachusetts, New Hampshire, the UK, Canada, and Australia, then sold through government procurement and retail pharmacy channels. The model depends on regulatory approval, reimbursement negotiation, and seasonal demand patterns, with gross margins currently negative due to inventory write-downs and capacity underutilization. The cost-reduction program aims to achieve $1.5 billion in annual savings by 2027, improving the path to profitability. The alliance model, particularly the Merck partnership for personalized cancer vaccines, shares development costs and provides validation without full capital commitment. The company's financial architecture is characterized by high fixed costs, seasonal revenue concentration, and a transition from profitable pandemic contracting to loss-making endemic commercialization. The path to cash break-even by 2028 depends on achieving $3-4 billion in annual revenue through successful launches of the flu vaccine, norovirus vaccine, and oncology products, combined with continued cost discipline.

Moderna Key Acquisitions

Moderna's acquisition strategy has focused on adding scientific capabilities and manufacturing technology rather than buying revenue. The 2023 acquisition of Carmot Therapeutics for $250 million added CRISPR-based gene editing technology and RNA-targeted small molecule capabilities, expanding the platform beyond mRNA into permanent genetic modification. The 2022 acquisition of OriCiro Genomics for $85 million added cell-free DNA amplification technology that improves mRNA manufacturing speed and efficiency, contributing to the 41% reduction in cost of sales achieved in 2025. These acquisitions contrast with the larger M&A strategies of competitors like Pfizer and AstraZeneca, reflecting Moderna's focus on platform enhancement rather than revenue diversification through blockbuster acquisitions. The company's partnership strategy has been equally important, with the Merck collaboration for personalized cancer vaccines worth up to $450 million and the AstraZeneca partnership for cardiovascular mRNA therapeutics worth up to $420 million providing non-dilutive funding and validation.

What Are the Biggest Risks Facing Moderna?

The biggest risk facing Moderna is the convergence of declining COVID revenue, failed near-term pipeline catalysts, and political hostility to mRNA technology, creating a funding crisis that could force dilutive capital raises. The company burns $3.5 billion annually and has only $6 billion in cash, giving it roughly two years of runway. The CMV vaccine Phase 3 failure, flu vaccine FDA Refusal-to-File, and mRESVIA commercial failure have eliminated near-term revenue diversification options. The Trump administration's HHS Secretary Robert F. Kennedy Jr. has withdrawn $766 million in pandemic vaccine funding and removed CDC recommendations for COVID vaccination in children and healthy pregnant women, eroding political and financial support for mRNA platforms. Competitive pressure in COVID vaccines from Pfizer and Novavax, and in RSV from GSK and Pfizer, has limited market share capture. The 2026 revenue guidance of up to 10% growth is modest and assumes no revenue from the flu vaccine or flu/COVID combination. If the 2026-2027 pipeline does not produce blockbuster approvals, Moderna may be forced to raise capital at depressed valuations or pursue a defensive merger.

Bottom Line

Moderna is in a critical transition period, with revenue declining 40% in 2025 to $1.9 billion and net losses of $2.8 billion, but operating expenses reduced by $2.2 billion, exceeding targets. The company has three approved products, a pipeline of 45+ programs, and $6 billion in cash, providing roughly two years of runway. The path to cash break-even by 2028 depends on successful launches of the flu vaccine, norovirus vaccine, and oncology products, combined with continued cost discipline. While the 90% share price decline from its 2021 peak reflects investor skepticism, the mRNA platform's proven speed and the $6 billion funding cushion provide optionality that could yield extraordinary returns if pipeline milestones are achieved. The outcome will determine whether Moderna becomes a sustainable pharmaceutical enterprise or a cautionary tale about pandemic-driven biotechnology volatility.

What Is Moderna's Pipeline?

Moderna's pipeline includes more than 45 development programs across four therapeutic areas: respiratory vaccines, latent viruses, rare diseases, and immuno-oncology. Key programs include mRNA-1010 for seasonal flu, which demonstrated 26.6% superior efficacy in Phase 3 but faces FDA regulatory hurdles; mRNA-1403 for norovirus, in Phase 3 with data expected in 2026; mRNA-4157 for personalized melanoma vaccines with Merck, in Phase 3 with data expected in 2026-2027; and mRNA-3704 and mRNA-3927 for methylmalonic acidemia and propionic acidemia, in early development. The company has also advanced mRNA-4359 for KRAS-mutated cancers and mRNA-6231 for autoimmune diseases. The pipeline reflects Moderna's platform strategy of applying mRNA across multiple therapeutic areas, with the goal of delivering up to 10 product approvals through 2027. The CMV vaccine failure in 2025 eliminated one near-term catalyst but freed resources for higher-priority programs. The success of this pipeline will determine whether Moderna can diversify beyond COVID vaccines and achieve sustainable revenue.

How Does Moderna's mRNA Technology Work?

Moderna's mRNA technology works by delivering synthetic messenger RNA encapsulated in lipid nanoparticles into human cells, where the cellular machinery translates the mRNA sequence into therapeutic proteins. Unlike traditional vaccines that use weakened or inactivated pathogens, or recombinant protein vaccines that require complex cell-culture manufacturing, mRNA vaccines instruct the body to produce the target protein itself, triggering immune responses. The platform's speed advantage comes from cell-free synthesis: once the genetic sequence of a target protein is known, mRNA can be manufactured in weeks rather than the months or years required for cell-culture or egg-based production. The lipid nanoparticle formulation protects the mRNA from degradation in the bloodstream and facilitates uptake into cells, a critical innovation developed through partnerships with Acuitas and Arbutus. The platform's flexibility allows rapid strain updates, as demonstrated by mNEXSPIKE, which was developed and approved within months of the LP.8.1 variant emergence. The technology's applicability extends beyond infectious diseases to cancer, where patient-specific neoantigens can be encoded, and rare diseases, where missing enzymes can be produced.

What Is Moderna's Cash Position?

Moderna ended 2025 with approximately $6 billion in cash, cash equivalents, and investments, down from $9.5 billion at year-end 2024. The company burned approximately $3.5 billion in cash during 2025, giving it roughly two years of runway at current burn rates before requiring additional capital. The 2026 revenue guidance of up to 10% growth and continued cost reductions aim to extend this runway. The company has filed a shelf registration for potential future securities offerings, providing flexibility to raise capital if needed. The path to cash break-even by 2028 depends on achieving $3-4 billion in annual revenue through successful product launches and continued cost discipline. The $6 billion cash position, while declining, still provides a funding advantage over smaller biotechnology competitors and enables the company to pursue high-risk, high-reward programs in oncology and rare diseases without immediate partnership pressure.

What Is Moderna's Stock Performance?

Moderna's stock has experienced one of the most dramatic trajectories in biotechnology history. The company's shares debuted at $23 in its December 2018 IPO, rose to a peak of $484 in August 2021 as Spikevax generated $17.7 billion in annual revenue, and have since declined to approximately $47 in June 2026, a 90% collapse that erased more than $160 billion in market value. The stock's volatility reflects the extreme dependence on COVID vaccine revenue and the market's uncertainty about the company's ability to diversify. At its peak, Moderna was the most valuable biotechnology company in the world, with a market capitalization exceeding $180 billion. Today, the company trades at approximately $18.8 billion, a price-to-sales ratio of 8.4x that is below the biotechnology sector average. The stock has attracted both institutional investors, including Vanguard, BlackRock, and State Street, and retail investors who were drawn to the pandemic narrative. The decline has been particularly painful for investors who bought near the peak, with the stock requiring a 10-fold increase to return to its all-time high. The company's share repurchase program, which has bought back approximately $3 billion in shares since 2022, has been criticized as a poor use of capital given the company's funding needs. The stock's future performance will depend on the company's ability to execute its pipeline, achieve cash break-even, and restore investor confidence in the mRNA platform's long-term potential.

What Are Moderna's Key Partnerships?

Moderna's strategic partnerships have been critical to its development and survival. The Merck collaboration, worth up to $450 million, focuses on personalized cancer vaccines using mRNA technology to encode patient-specific neoantigens. The partnership has produced promising Phase 2 data for mRNA-4157 in melanoma, with a 44% reduction in recurrence risk when combined with Keytruda, and is now in Phase 3 with data expected in 2026-2027. The AstraZeneca partnership, worth up to $420 million, targets cardiovascular, metabolic, and renal diseases using mRNA therapeutics, though these programs remain in early development. The government partnerships with the UK, Canada, Australia, Mexico, and Taiwan provide long-term manufacturing commitments and revenue visibility through 2028. The UK agreement includes a commitment to produce 250 million doses annually at the Wrexham facility, while the Canadian and Australian agreements support domestic manufacturing for national immunization programs. These partnerships provide non-dilutive funding and political capital that stabilize the business during the transition from pandemic to endemic markets. The company's ability to maintain and expand these partnerships will be critical for revenue diversification and manufacturing utilization.

How Has Moderna Managed Costs?

Moderna has implemented one of the most aggressive cost-reduction programs in biotechnology history, reducing annual operating expenses by $2.2 billion in 2025, exceeding the original target of $2.0 billion. The cost reductions have been achieved through multiple levers: R&D portfolio prioritization, which eliminated lower-priority programs and focused resources on the highest-probability candidates; manufacturing rightsizing, which reduced capacity and renegotiated supplier contracts to align with seasonal demand; workforce reduction, which cut headcount by 10% from 5,800 to fewer than 4,800; and administrative efficiency, which reduced SG&A expenses by 13%. The cost of sales declined 41% year-over-year, from $1.47 billion in 2024 to $868 million in 2025, despite lower volumes, reflecting operational improvements and contract renegotiations. The R&D expenses declined 31% to $3.1 billion, as the company wound down large Phase 3 respiratory programs and deprioritized early-stage research. The company expects additional cost savings in 2026, with a target of $1.5 billion in total savings by 2027 compared to 2024 levels. The cost-reduction program has been necessary for survival but has also raised concerns about the company's ability to maintain innovation capacity and retain scientific talent.

What Is Moderna's Manufacturing Strategy?

Moderna's manufacturing strategy has evolved from pandemic-scale expansion to regional localization. The company operates facilities in Massachusetts, New Hampshire, the UK, Canada, and Australia, with total capacity exceeding 500 million doses annually. The Norwood, Massachusetts facility, which was built during the pandemic to produce hundreds of millions of doses, now operates at a fraction of capacity, contributing to unutilized capacity costs and inventory write-downs. The international facilities, which opened in 2024-2025, are producing locally manufactured vaccines for national immunization programs, reducing logistics costs and meeting procurement preferences for domestic production. The UK facility in Wrexham has a commitment to produce 250 million doses annually, while the Canadian and Australian facilities support national programs. The manufacturing process uses cell-free synthesis, which provides flexibility to switch between products but is less efficient than dedicated cell-culture lines for stable demand. The company has renegotiated supplier contracts and reduced third-party manufacturing dependencies to lower costs. The manufacturing strategy is critical to the company's ability to compete in seasonal vaccine markets and respond to future pandemics, but the current underutilization creates a structural cost burden that must be resolved through revenue growth or further capacity reduction.

What Is the Future of mRNA Technology?

The future of mRNA technology is at a crossroads, with Moderna's experience highlighting both the platform's extraordinary potential and its significant limitations. The technology's speed advantage, demonstrated by the 11-month development of Spikevax, is unmatched by traditional vaccine platforms and could be transformative for responding to emerging pathogens. The platform's flexibility, enabling rapid strain updates and product switching, provides manufacturing advantages that cell-culture processes cannot match. The applicability across therapeutic areas, from infectious diseases to cancer to rare diseases, creates optionality that single-modality platforms cannot match. However, the challenges demonstrated by Moderna's post-pandemic struggles, including negative gross margins, inventory write-downs, and commercial execution failures, show that platform technology alone is insufficient without sustainable business models. The political hostility to mRNA technology in the United States, while potentially temporary, has created headwinds that could slow adoption and funding. The competitive landscape, with BioNTech, CureVac, and other companies also developing mRNA platforms, is intensifying. The future of mRNA will depend on whether the technology can demonstrate superior efficacy and cost-effectiveness in non-pandemic applications, whether regulatory pathways remain open for novel mRNA products, and whether public and political acceptance can be restored. Moderna's success or failure in the 2026-2027 period will be a critical test case for the technology's long-term viability.

What Is Moderna's R&D Strategy?

Moderna's R&D strategy is built on platform biotechnology, leveraging its proprietary mRNA technology across multiple therapeutic areas to maximize the return on platform investment. The company invests $3.1 billion annually in R&D, down from $4.5 billion in 2024, reflecting portfolio prioritization and cost discipline. The R&D organization includes more than 3,000 researchers and has produced more than 45 development programs. The strategy focuses on four therapeutic areas: respiratory vaccines, where the company aims to establish a seasonal franchise including COVID, flu, and RSV; latent viruses, including CMV and norovirus, where mRNA's speed advantage could address significant unmet needs; rare diseases, where mRNA could provide enzyme replacement for genetic disorders; and immuno-oncology, where personalized cancer vaccines could transform treatment paradigms. The portfolio prioritization process, implemented in 2023, has eliminated lower-priority programs and focused resources on candidates with the highest probability of success and near-term revenue potential. The CMV vaccine failure in 2025 eliminated one near-term catalyst but freed resources for higher-priority programs. The flu vaccine, while facing regulatory hurdles, remains the most important near-term revenue opportunity. The norovirus vaccine, with Phase 3 data expected in 2026, could enter a market with no approved competitors. The personalized cancer vaccine with Merck, if Phase 3 data is positive, could validate mRNA in oncology and establish a new treatment paradigm. The rare disease programs, while long-term, target ultra-rare diseases with no approved treatments and could command premium pricing. The R&D strategy also includes investments in manufacturing technology, including the OriCiro acquisition for DNA amplification and internal process improvements that have reduced cost of sales by 41%. The company's ability to maintain R&D productivity while reducing spending will determine whether it can achieve the pipeline targets necessary for revenue diversification.

What Is Moderna's Path to Profitability?

Moderna's path to profitability depends on achieving cash break-even by 2028 through a combination of revenue growth and cost reduction. The 2026 revenue guidance projects up to 10% growth, to approximately $2.1 billion, with a 50-50 U.S.-international sales mix. The company expects to reduce operating expenses further in 2026, building on the $2.2 billion reduction achieved in 2025. The path to break-even requires achieving $3-4 billion in annual revenue, which would require successful launches of the flu vaccine, norovirus vaccine, and oncology products, combined with continued cost discipline. The flu vaccine, if approved in 2026 or 2027, could generate $500 million to $1 billion annually in a $5 billion global market. The norovirus vaccine, if approved, could enter a market with no competitors and generate significant first-mover revenue. The oncology programs, particularly the personalized cancer vaccine with Merck, could command premium pricing if Phase 3 data is positive. The rare disease programs, while smaller markets, could provide high-margin revenue with limited competition. The company's cost structure must also improve, with manufacturing utilization increasing and inventory write-downs declining as demand stabilizes. The company's ability to achieve these targets depends on regulatory approvals, commercial execution, and competitive dynamics that are partially outside its control. The $6 billion cash position provides a buffer, but the two-year runway creates urgency around milestone achievement. If the company fails to achieve break-even by 2028, it may be forced to raise additional capital, pursue strategic partnerships on unfavorable terms, or become an acquisition target.

How Does Moderna Compare to BioNTech?

Moderna and BioNTech are the two leading mRNA platform companies, with similar origins in academic research and venture capital funding but divergent post-pandemic trajectories. BioNTech, founded in 2008 in Germany, partnered with Pfizer for the Comirnaty COVID vaccine and has maintained a more diversified pipeline including oncology, infectious diseases, and autoimmune therapies. BioNTech's revenue has also declined from pandemic peaks but the company has been more successful in maintaining commercial partnerships and diversifying its revenue base. BioNTech's market capitalization, while also down from peaks, has been more stable than Moderna's, reflecting investor confidence in the company's pipeline breadth and European regulatory relationships. The two companies compete directly in personalized cancer vaccines, with both developing mRNA-encoded neoantigen approaches in combination with checkpoint inhibitors. Moderna's partnership with Merck and BioNTech's partnership with Genentech/Roche represent the two leading programs in this space. In infectious diseases, Moderna has focused on respiratory vaccines while BioNTech has pursued a broader range including malaria, tuberculosis, and HIV. The competitive dynamics between the two companies will shape the mRNA landscape, with success in oncology and rare diseases potentially determining which platform becomes the dominant modality. Moderna's manufacturing infrastructure, with facilities in five countries, provides geographic advantages that BioNTech's more concentrated European footprint cannot match. However, BioNTech's deeper relationships with European regulators and academic institutions provide advantages in a market that represents a significant portion of global pharmaceutical revenue.

What Are Moderna's International Operations?

Moderna operates in 18 countries with manufacturing facilities in the United States, UK, Canada, and Australia. The international strategy has shifted from export-based distribution to regional localization, with facilities producing vaccines for national immunization programs. The UK facility in Wrexham, opened in 2024, has a commitment to produce 250 million doses annually and employs several hundred workers. The Canadian facility, opened in 2024, supports the Canadian government's pandemic preparedness and seasonal vaccination programs. The Australian facility, opened in 2025, produces vaccines for the Australian and regional markets. These facilities provide political capital and procurement advantages, as governments prefer domestically manufactured vaccines for national security and supply chain resilience reasons. The international revenue contribution has grown from 38% of net product sales in 2025 to a targeted 50% in 2026, reflecting the company's strategy to diversify beyond the U.S. market. The international partnerships, including long-term agreements with Mexico and Taiwan, provide revenue visibility and manufacturing commitments that stabilize cash flows. The company's ability to manage international operations, including regulatory compliance, supply chain logistics, and local workforce management, will be critical for executing the geographic expansion strategy. The international facilities, while capital-intensive, create barriers to entry for competitors who lack global manufacturing footprints and provide optionality for responding to regional demand surges or pandemic emergence.

What Is Moderna's Role in Pandemic Preparedness?

Moderna's role in pandemic preparedness has evolved from emergency contractor to strategic partner for national governments. During the COVID-19 pandemic, the company produced billions of doses and became a critical supplier for governments worldwide. In the post-pandemic period, the company has secured long-term agreements with the UK, Canada, Australia, Mexico, and Taiwan that include stand-ready manufacturing commitments, ensuring that capacity can be rapidly activated if a new pathogen emerges. The company's platform speed, with the ability to develop new vaccine candidates in months, provides a unique capability for responding to emerging threats. The U.S. government's Project NextGen, which includes funding for next-generation vaccine technologies, could provide additional support for Moderna's pandemic preparedness efforts, though the Trump administration's skepticism of mRNA technology has created uncertainty about future funding. The company's manufacturing infrastructure, while currently underutilized for seasonal demand, provides surge capacity that could be activated in a pandemic scenario. The international facilities create a distributed manufacturing network that reduces supply chain risks and ensures regional access to vaccines. The company's role in pandemic preparedness is therefore a strategic asset that provides revenue stability through stand-ready agreements and creates optionality for future pandemic responses. However, the value of this asset depends on government willingness to fund preparedness and public acceptance of mRNA vaccines, both of which are currently uncertain.

Moderna, Inc. Key Facts

Data Verified

Company	Moderna, Inc.
Trajectory	Stable
Financials	$1.9B (FY2025, last reviewed July 2025) ^[1]
Market Cap	$18.8B ^[2]
Last reviewed	By Swet Parvadiya, Founder & Editor - May 2026
Founded	2010
Founder(s)	Derrick Rossi, Robert Langer, Noubar Afeyan, and Kenneth Chien
CEO	Stéphane Bancel
Headquarters	Cambridge, Massachusetts
Industry	Biotechnology and mRNA Therapeutics
Employees	4,800+ ^[3]

Moderna, Inc. Revenue, History, and Strategy

"Moderna's share price has collapsed from a peak of $484 in August 2021, when the company's COVID vaccine generated $17.7 billion in annual revenue and its market capitalization exceeded $180 billion, to approximately $47 in June 2026, a 90% decline that erased more than $160 billion in shareholder value. The company now generates $1.9 billion in annual revenue, down from $18.4 billion in 2022, and has reported net losses exceeding $2.8 billion in both 2024 and 2025. Yet CEO Stéphane Bancel is betting that Moderna can transform from a pandemic one-hit wonder into a diversified biotechnology company with 10 product approvals by 2027, a $6 billion cash cushion, and a proprietary mRNA platform that has already proven it can develop vaccines in months rather than years. The outcome of this bet will determine whether Moderna becomes a sustainable pharmaceutical enterprise or a cautionary tale about the volatility of platform biotechnology. The company's scientific team, which includes researchers who have been with Moderna since its founding and have deep expertise in mRNA chemistry and manufacturing, remains one of the most talented groups in biotechnology. The company's patent portfolio, which includes more than 1,400 patents and patent applications, protects its intellectual property and provides licensing opportunities. The company's manufacturing infrastructure, while currently underutilized, provides surge capacity that could be activated in a future pandemic. The company's international partnerships, which include long-term agreements with multiple governments, provide revenue visibility and political capital. The outcome of Moderna's transformation will determine whether mRNA technology becomes a permanent fixture in medicine or a footnote in pandemic history."

Why Moderna, Inc. Wins

Moderna wins when speed matters. The company's mRNA platform enabled the development of Spikevax from sequence selection to FDA authorization in 11 months, a timeline that no traditional vaccine manufacturer could match. This speed advantage, combined with cell-free manufacturing flexibility, allows Moderna to respond to emerging pathogens and update strains faster than competitors. The platform's ability to encode any protein sequence creates optionality across infectious diseases, cancer, and rare diseases that single-product companies cannot match. The $6 billion cash position provides funding for high-risk, high-reward programs that smaller biotechs cannot afford. The company's ability to develop mNEXSPIKE from sequence selection to approval in months, rather than the years required by traditional platforms, demonstrates the competitive advantage of speed in responding to variant emergence. The cell-free manufacturing process provides flexibility that allows rapid product switching, creating operational advantages that cell-culture manufacturers cannot match. The $6 billion cash position provides funding for high-risk programs that smaller competitors cannot afford, and the scientific talent base represents intellectual capital that is difficult to replicate. The company's data analytics capabilities, which track vaccine distribution and effectiveness in real-time, provide commercial insights that competitors with less mature data infrastructures cannot match. The regulatory relationships, built through rapid approvals, provide advantages in navigating complex pathways. The manufacturing quality systems, validated at pandemic scale, provide quality assurance that is difficult to replicate. The ESG commitments attract investors and employees who prioritize sustainability. The patient advocacy relationships provide a foundation for market access.

Moderna, Inc. operates in a competitive market alongside Pfizer Inc., Gilead Sciences, Inc., Regeneron Pharmaceuticals, Inc.. Analysts frequently compare Moderna, Inc. and Pfizer Inc. due to their overlapping products, target markets, and strategic positioning.

Moderna, Inc. is a biotechnology company that generated $1.944 billion in Total Revenue in fiscal year 2025 and employs approximately 4,800 people across 18 countries. The company makes money primarily through sales of mRNA vaccines, with Net Product Sales of $1.818 billion in 2025, including Spikevax for COVID-19, mNEXSPIKE as a next-generation COVID vaccine, and mRESVIA for RSV prevention. Founded in September 2010 by Derrick Rossi, Robert Langer, Noubar Afeyan, and Kenneth Chien, Moderna pioneered mRNA therapeutics and rose to prominence during the COVID-19 pandemic when Spikevax generated $17.7 billion in peak annual revenue. The company now targets cash break-even by 2028 through cost reduction, pipeline diversification, and geographic expansion. The company employs approximately 4,800 people across 18 countries and ended 2025 with $6 billion in cash. Moderna's mRNA platform technology enables rapid vaccine development, with Spikevax developed from sequence selection to FDA authorization in 11 months. The company now targets cash break-even by 2028 through cost reduction, pipeline diversification, and geographic expansion. The company's manufacturing network includes facilities in five countries with capacity exceeding 500 million doses annually. The strategic partnerships with governments provide revenue visibility through 2028. The pipeline of 45+ programs spans respiratory vaccines, latent viruses, rare diseases, and immuno-oncology. The company's survival depends on successful pipeline execution, cost discipline, and the ability to navigate political and competitive headwinds.

Revenue

$1.9B

Founded

2010

Employees

5K+

Market Cap

$18.8B

Author: CorpDigest Research DeskProfile updated: July 15, 2025 · Verified Accuracy

Key Facts

Founded: Moderna, Inc. was established in 2010 and is headquartered in Cambridge, Massachusetts.
Revenue: Moderna, Inc. reported $17.7B in annual revenue (2021).
Valuation: Market capitalization of approximately $18.8B.
Scale: Moderna, Inc. employs 4,800 people globally.
Business Model: Moderna generates revenue through three primary streams that together produced $1.944 billion in fiscal year 2025: Net.
Competitive Edge: Moderna's single most defensible competitive moat is its proprietary mRNA platform technology, which has demonstrated.

How Moderna, Inc. Makes Money

Capital Allocation & Scaling Mechanics

Moderna generates revenue through three primary streams that together produced $1.944 billion in fiscal year 2025: Net Product Sales, Collaboration Revenue, and Other Revenue. Net Product Sales constitute the overwhelming majority of the business, generating $1.818 billion in 2025, down from $3.109 billion in 2024, and representing approximately 94% of Total Revenue. This stream includes direct sales of Spikevax, mNEXSPIKE, and mRESVIA to government procurement agencies, retail pharmacies, hospital systems, and international distributors. product sales totaled $1.2 billion, or 62% of net product sales, while international sales contributed $745 million, or 38%. revenue concentration reflects the seasonal nature of COVID and RSV vaccination, with demand concentrated in fall and winter months. The Other Revenue stream, which includes grant revenue, collaboration milestones, and stand-ready manufacturing revenue from long-term strategic partnerships, added $126 million in 2025. Collaboration Revenue from partnerships with Merck, AstraZeneca, and other biotechnology companies has historically contributed to Moderna's financials but declined as the company focused on proprietary products. The loss of Spikevax Product Sales would be catastrophic to Moderna's current financial architecture; COVID vaccine sales generated $1.8 billion in 2025 and remain the company's dominant revenue source, though declining at double-digit rates as the market transitions from pandemic to endemic. The mNEXSPIKE next-generation vaccine, approved in 2025, represented approximately 24% of all U.S. retail COVID vaccinations in its first year, generating an estimated $400-500 million in revenue. The mRESVIA RSV vaccine, approved in 2024 and expanded to high-risk adults 18-59 in 2025, generated negligible sales amid competition from Pfizer's Abrysvo and GSK's Arexvy, which together dominate the $1.5 billion RSV vaccine market. Moderna's cost of sales was $868 million in 2025, or 48% of net product sales, including $88 million in third-party royalties and $291 million in inventory write-downs. This cost structure reflects the challenges of maintaining pandemic-scale manufacturing capacity for seasonal demand, with unutilized manufacturing capacity and wind-down costs contributing to margin pressure. The company's gross margin is negative when including inventory write-downs and capacity underutilization, a structural problem that the cost-reduction program aims to address. Research and development expenses were $3.1 billion in 2025, a 31% decrease from $4.5 billion in 2024, reflecting the wind-down of large Phase 3 respiratory programs and portfolio prioritization. Selling, general, and administrative expenses were $1.0 billion in 2025, a 13% decrease from 2024. The company's business model depends on a global commercial infrastructure of approximately 1,000 sales and marketing employees who operate in 18 countries, selling to government health agencies, pharmacy chains, and physician practices. The model also depends on maintaining manufacturing capacity at facilities in Massachusetts, New Hampshire, and international sites in the UK, Canada, and Australia, even as demand fluctuates seasonally. The company's revenue model is therefore characterized by high fixed costs, seasonal demand concentration, and a transition from government advance purchase agreements to retail commercial sales, creating significant financial volatility. The company's supply chain strategy includes dual sourcing for critical raw materials such as lipid components and nucleotides, reducing dependence on single suppliers and ensuring continuity of production. The regional distribution centers in the United States, Europe, and Asia-Pacific reduce shipping costs and improve product availability for seasonal vaccination campaigns. The company's quality systems, which were built to support pandemic-scale production of billions of doses, provide a foundation for maintaining compliance across multiple facilities and products, but also create fixed costs that are difficult to reduce proportionally with volume declines. The company's patient support programs, including financial assistance for uninsured patients and vaccination education initiatives, aim to improve access and adherence, but these programs add to the cost structure without generating direct revenue. The company's digital health initiatives, including mobile applications for vaccination scheduling and reminder systems, could improve patient engagement and provide commercial insights, but require ongoing investment in software development and data analytics. The company's environmental commitments, including carbon neutrality goals for manufacturing operations, reflect stakeholder expectations but add to operational costs. The integration of these operational capabilities into a cohesive commercial strategy is a significant challenge for a company that has historically focused on scientific development rather than commercial execution. The business model must therefore evolve from a pandemic-focused, government-contracting model to a diversified, commercially-driven model that can generate sustainable profits in competitive markets.

Explore Moderna, Inc. In Depth

📅Moderna, Inc. History & Milestones 💼How Moderna, Inc. Makes Money 📊Moderna, Inc. Revenue & Financials ⚔️Moderna, Inc. Competitive Strategy & SWOT 👤Moderna, Inc. Founders & Origin Story 🏆Moderna, Inc. CEO History & Leadership 🤝Moderna, Inc. Acquisitions & Deals

Strategic Corporate Direction

Moderna's growth strategy rests on four pillars that collectively aim to deliver cash break-even by 2028 and establish a sustainable biotechnology enterprise. First, respiratory vaccine franchise expansion requires maintaining COVID vaccine share through mNEXSPIKE strain updates, growing mRESVIA RSV sales through expanded indications and international partnerships, and launching the seasonal flu vaccine (mRNA-1010) to capture share of the $5 billion global flu market. The company has secured long-term agreements with Mexico and Taiwan for respiratory vaccines and is prioritizing Europe as a significant market despite a competitor contract still in effect. Second, pipeline diversification into oncology and rare diseases depends on advancing mRNA-4157 in melanoma with Merck, expanding into other tumor types, and progressing mRNA-3704 and mRNA-3927 for methylmalonic acidemia and propionic acidemia. The oncology strategy leverages Moderna's ability to encode patient-specific neoantigens, creating personalized vaccines that could command premium pricing. Third, cost reduction and operational efficiency targets $1.5 billion in annual operating expense reductions by 2027, achieved through R&D portfolio prioritization, manufacturing rightsizing, workforce reduction, and supplier contract renegotiations. The company has already exceeded its 2025 cost-reduction target by $200 million and expects additional savings in 2026. Fourth, geographic expansion and manufacturing localization involves operating newly opened facilities in the UK, Canada, and Australia to produce locally manufactured vaccines, reducing logistics costs and meeting national procurement preferences. The company also plans to begin selling locally manufactured products in the UK and Australia in 2026, which is the largest driver of international growth. Each of these pillars carries specific financial targets: respiratory vaccines must grow from $1.8 billion in 2025 to $3-4 billion by 2028; oncology and rare diseases must generate initial revenue by 2027-2028; and operating expenses must decline to $3.5 billion annually from $5.0 billion in 2025. The growth strategy is underpinned by the $6 billion cash position, which provides funding for two years of development, but also creates pressure to achieve milestones before requiring additional capital. The company's ability to pivot from pandemic-scale operations to a leaner, focused model will determine whether it can execute this strategy successfully. The company's ability to execute this strategy while managing cash burn, regulatory risk, and commercial execution will determine whether it can achieve the 2028 cash break-even target. The strategy also includes investments in digital health and patient engagement, including mobile applications and reminder systems that could improve vaccination rates and brand loyalty. The company's data science capabilities, which were developed during the pandemic to track vaccine distribution and effectiveness, could be leveraged for commercial insights and patient targeting. The manufacturing quality systems, which were built to pandemic standards, provide a foundation for maintaining compliance across multiple facilities and products. The company's regulatory affairs team, which managed the rapid approval of Spikevax, has experience with accelerated pathways that could be applied to future products. The growth strategy is therefore not merely a collection of product launches but an integrated approach that leverages the company's platform capabilities, manufacturing infrastructure, scientific talent, and strategic partnerships to create sustainable competitive advantages. The success of this integrated approach depends on flawless execution across multiple dimensions, including clinical development, regulatory approval, manufacturing scale-up, commercial launch, and cost management. The company's ability to maintain focus and discipline while navigating these challenges will determine whether it can complete the transformation from pandemic contractor to diversified biotechnology enterprise. The company's data analytics capabilities, which were developed during the pandemic, could be leveraged for commercial insights, patient targeting, and product development. The digital health initiatives, including mobile applications and reminder systems, could improve vaccination rates and brand loyalty. The manufacturing quality systems, built to pandemic standards, provide a foundation for maintaining compliance across multiple facilities and products. The regulatory affairs team, which managed the rapid approval of Spikevax, has experience with accelerated pathways that could be applied to future products. The patient support programs, including financial assistance and vaccination education, aim to improve access and adherence. The ESG commitments, including carbon neutrality and diversity goals, reflect stakeholder expectations and could attract investors and employees. The integration of these capabilities into a cohesive commercial strategy is essential for achieving sustainable growth. The company's ability to execute this integrated strategy while managing cash burn, regulatory risk, and competitive pressure will determine whether it can complete the transformation from pandemic contractor to diversified biotechnology enterprise.

Where the Money Comes From

Moderna reported Total Revenue of $1.944 billion for fiscal year 2025, a 40% decrease from the $3.236 billion recorded in 2024, reflecting the continued collapse of COVID-19 vaccine demand from pandemic peaks. Net product sales were $1.818 billion, down from $3.109 billion in 2024, with U.S. sales of $1.2 billion and international sales of $745 million. The company reported a GAAP net loss of $2.822 billion, or $7.26 per share, compared to a net loss of $3.561 billion, or $9.28 per share, in 2024, representing a 21% improvement in net loss despite the revenue decline. This improvement was driven by cost reductions: cost of sales declined 41% to $868 million, R&D expenses declined 31% to $3.1 billion, and SG&A expenses declined 13% to $1.0 billion. Total operating expenses were $5.018 billion in 2025, down from $7.181 billion in 2024, reflecting the company's aggressive cost-cutting program. The gross margin on product sales remained negative when including inventory write-downs of $291 million and unutilized manufacturing capacity costs. Interest income contributed $314 million, partially offsetting operating losses. The company ended 2025 with cash, cash equivalents, and investments of approximately $6 billion, down from $9.5 billion at year-end 2024, representing a cash burn rate of approximately $3.5 billion for the year. The 2026 revenue guidance projects up to 10% growth, to approximately $2.1 billion, with a 50-50 U.S.-international sales mix compared to 62% U.S. in 2025. The company expects to reduce operating expenses further in 2026, with a target of $1.5 billion in total cost savings by 2027 compared to 2024 levels. Capital expenditures in 2025 were approximately $0.3 billion, down from previous expectations of $0.4 billion, as the company deferred non-essential infrastructure projects. The financial architecture is characterized by high fixed costs, seasonal revenue concentration, and a transition from profitable pandemic contracting to loss-making endemic commercialization. The path to cash break-even by 2028 depends on achieving $3-4 billion in annual revenue, which would require successful launches of the flu vaccine, norovirus vaccine, and oncology products, combined with continued cost discipline. The company's market capitalization of approximately $18.8 billion as of June 2026 reflects investor skepticism about the near-term revenue trajectory, with the stock trading at a price-to-sales ratio of approximately 8.4x, below the biotechnology sector average. The balance sheet provides roughly two years of runway at current burn rates, creating urgency around pipeline execution and potential capital raising if milestones are delayed. The company's capital structure, which includes no significant long-term debt, provides flexibility but also limits access to debt markets for additional funding. The company's equity financing history, which includes multiple public offerings and the 2018 IPO, demonstrates access to capital markets but at increasingly dilutive terms. The company's share repurchase program, which has consumed $3 billion in cash since 2022, has been criticized as a poor use of capital given the company's funding needs and declining share price. The company's institutional shareholder base, which includes Vanguard, BlackRock, and State Street, has remained relatively stable, providing some support for the stock price, but these investors may reduce positions if the company's financial performance does not improve. The company's analyst coverage, which includes more than 20 investment banks, provides visibility but also creates pressure to meet quarterly expectations. The company's credit rating, while not formally rated by major agencies, would likely be speculative grade given the company's net losses and declining cash position. The company's ability to access capital markets, whether through equity offerings, debt financing, or strategic partnerships, will be critical for funding the pipeline and achieving cash break-even. The financial narrative is therefore one of a company that has experienced extraordinary financial volatility, from pandemic profitability to endemic losses, and must now navigate a funding environment that is increasingly skeptical of biotechnology companies with unproven commercial models.

Financial Metric	Estimated Value (2026)
Market Capitalization	$18.8B
Employee Count	4,800 +
Latest Annual Revenue	$17.7B (2021)

Historical Revenue Chart

Moderna, Inc. Annual Revenue History

Verified annual revenue figures from SEC filings and official earnings reports. All figures in USD.

Fiscal Year	Annual Revenue	YoY Change
FY2021	$17.7B	N/A
FY2022	$18.4B	+4.0%
FY2023	$6.8B	-63.0%
FY2024	$3.2B	-52.4%
FY2025	$1.9B	-39.9%

Source: SEC EDGAR filings, annual earnings releases, and verified financial disclosures.

SWOT Analysis: Moderna, Inc.

Strengths

Moderna's mRNA platform enabled the development of Spikevax from sequence selection to Phase 1 in 63 days and FDA authorization in 11 months, validating the platform's speed and flexibility. This capability creates a competitive advantage in responding to emerging pathogens and enables rapid strain updates for seasonal vaccines. The platform's cell-free manufacturing process provides flexibility that traditional cell-culture vaccine manufacturing cannot match. This factor has been validated by financial performance, market data, and competitive dynamics observed over multiple reporting periods.

Weaknesses

Moderna's revenue has declined 89% from its 2021 peak, with the company reporting net losses of $2.8-3.6 billion in 2024 and 2025. The cash burn rate of approximately $3.5 billion annually reduces the $6 billion cash position to roughly two years of runway. The negative gross margin on product sales, including $291 million in inventory write-downs, reflects structural challenges in scaling manufacturing for seasonal demand. This factor has been validated by financial performance, market data, and competitive dynamics observed over multiple reporting periods.

Opportunities

Moderna's mRNA-1010 flu vaccine demonstrated superior efficacy in Phase 3 and could disrupt the $5 billion seasonal flu market if regulatory hurdles are overcome. The mRNA platform enables faster strain updates than egg-based manufacturing, potentially providing a competitive advantage in responding to antigenic drift. Success in flu would validate mRNA for seasonal vaccines beyond COVID and diversify revenue. This factor has been validated by financial performance, market data, and competitive dynamics observed over multiple reporting periods.

Threats

The Trump administration's HHS Secretary Robert F. Kennedy Jr. has withdrawn $766 million in pandemic vaccine funding and removed CDC recommendations for COVID vaccination in children and healthy pregnant women. This political headwind erodes public confidence in mRNA technology, affects government procurement, and creates uncertainty about future funding. The hostility is specific to mRNA platforms and does not affect traditional vaccine competitors. This factor has been validated by financial performance, market data, and competitive dynamics observed over multiple reporting periods.

Market Rivals & Competitor Analysis

Moderna operates in the global biotechnology and vaccine market, where it competes directly with Pfizer, BioNTech, GSK, Sanofi, Novavax, Johnson & Johnson, and Merck for vaccine and therapeutic market share. In COVID-19 vaccines, Moderna held approximately 24% of the U.S. retail market in 2025 through mNEXSPIKE, behind Pfizer's Comirnaty which maintains dominant share through earlier market entry and broader distribution relationships. The global COVID vaccine market has collapsed from $50 billion in 2021 to approximately $5 billion in 2025, with all manufacturers experiencing revenue declines of 70% or more. In RSV vaccines, Moderna's mRESVIA has failed to gain traction against Pfizer's Abrysvo and GSK's Arexvy, which together captured more than 90% of the $1.5 billion RSV vaccine market in 2025. GSK's Arexvy, approved first in 2023, established a dominant position through superior clinical data and commercial execution, while Pfizer's Abrysvo leveraged the company's existing vaccine infrastructure. Moderna's late entry and limited commercial experience in seasonal vaccines have hampered its competitive position. In seasonal flu vaccines, Moderna faces entrenched competitors Sanofi, GSK, and Seqirus, which together supply more than 90% of the global market. The flu vaccine market is characterized by low margins, high volume, and established distribution relationships that are difficult for new entrants to penetrate. Moderna's mRNA-1010, while demonstrating superior efficacy in Phase 3, must overcome these structural barriers to achieve meaningful market share. In oncology, Moderna competes with a different set of players, including BioNTech, which is also developing personalized mRNA cancer vaccines, and traditional immuno-oncology companies like Bristol Myers Squibb and Merck. The mRNA-4157/Keytruda combination faces competition from other checkpoint inhibitor combinations and emerging cell therapy approaches. In rare diseases, Moderna's mRNA-3704 for methylmalonic acidemia and mRNA-3927 for propionic acidemia are in early development, competing against gene therapy approaches from companies like Sarepta Therapeutics and Novartis. The competitive landscape is therefore bifurcated: in respiratory vaccines, Moderna is a challenger with limited commercial scale; in oncology and rare diseases, it is a platform innovator with unproven commercial capabilities. The company's $6 billion cash position provides a funding advantage over smaller competitors, but Pfizer, GSK, and Sanofi have vastly larger balance sheets and commercial infrastructures. Moderna's competitive position is strengthened by its platform speed, with the ability to develop new vaccine candidates in months rather than years, but weakened by its lack of commercial experience outside the pandemic context and its dependence on seasonal demand patterns. The political environment has also shifted against mRNA technology, with the Trump administration's skepticism creating a headwind that traditional vaccine platforms do not face. The company's manufacturing flexibility, allowing rapid product switching across the mRNA platform, provides a competitive advantage in responding to variant emergence, but this advantage is less valuable in stable endemic markets. The global vaccine market is experiencing a structural shift from government procurement to commercial retail, with patients increasingly responsible for vaccine costs through insurance co-pays and deductibles. This shift creates pricing pressure and reimbursement challenges that government procurement did not face, particularly for seasonal vaccines where patients may choose not to vaccinate if costs are perceived as high. Moderna's mRNA vaccines, which have higher manufacturing costs than traditional egg-based or cell-culture vaccines, may face particular pricing pressure in this environment. The company's ability to demonstrate superior efficacy, as it did with mRNA-1010's 26.6% improvement over standard flu vaccines, could justify premium pricing, but reimbursement systems may not adequately capture efficacy differences. The competitive dynamics in oncology are also evolving, with cell therapy companies like Novartis and Gilead establishing commercial infrastructures and approved products, and checkpoint inhibitors like Keytruda and Opdivo dominating the immuno-oncology landscape. Moderna's personalized cancer vaccine approach, while differentiated, must demonstrate superior efficacy to justify the complexity and cost of patient-specific manufacturing. The company's partnership with Merck provides access to Keytruda's commercial infrastructure, but the combination must compete against established standards of care and emerging therapies. In rare diseases, the competitive landscape includes gene therapy companies like Sarepta and Novartis, which offer permanent cures rather than chronic enzyme replacement. The mRNA approach, while potentially safer and easier to manufacture, may struggle to compete with one-time treatments that offer definitive cures. The pricing dynamics in rare diseases, where treatments can command millions of dollars per patient, could favor gene therapies if they demonstrate durable efficacy. Moderna's rare disease programs, including mRNA-3704 and mRNA-3927, are in early development and face years of clinical trials before potential approval. The competitive landscape is therefore characterized by entrenched incumbents in established markets, high barriers to entry in seasonal vaccines, and intense competition in emerging therapeutic areas where Moderna's platform advantages are less proven. The data analytics and digital health capabilities of competitors like Pfizer and GSK, which have invested billions in health informatics and patient engagement platforms, provide advantages in understanding market dynamics and optimizing commercial execution. Moderna's data capabilities, while developed during the pandemic, are less mature and integrated than those of established pharmaceutical companies. The regulatory relationships of competitors, which have been built over decades of interactions with FDA and international agencies, provide advantages in navigating complex approval pathways and addressing regulatory concerns. Moderna's regulatory team, while experienced with accelerated approvals, has less depth in traditional regulatory strategy for seasonal vaccines and combination products. The manufacturing quality systems of competitors, which have been validated over decades of production, provide advantages in ensuring consistent product quality and meeting regulatory requirements. Moderna's quality systems, while robust, are less proven in the context of seasonal production with frequent strain changes and product switches. The ESG commitments of competitors, which are increasingly important for investor and stakeholder relations, provide advantages in attracting capital and talent. Moderna's ESG commitments, while genuine, are less established and may be perceived as less credible given the company's financial stress. The patient advocacy relationships of competitors, which have been built over decades of engagement with disease-specific organizations, provide advantages in market access and patient support. Moderna's advocacy relationships, while strong in the pandemic context, are less developed in seasonal vaccines and oncology. The competitive landscape is therefore characterized by entrenched advantages in commercial infrastructure, data analytics, regulatory relationships, and stakeholder engagement that Moderna must overcome to achieve sustainable growth.

Top Competitors	Head-to-Head Analysis

Detailed Historical Timeline

Historical Timeline & Strategic Pivots

Key Milestones

2005 - Karikó and Weissman Publish Modified mRNA Research

Katalin Karikó and Drew Weissman at the University of Pennsylvania publish foundational research demonstrating that modified nucleosides in mRNA can evade the body's inflammatory response, solving the key obstacle preventing mRNA therapeutics from clinical application. This discovery, later recognized with the 2023 Nobel Prize in Physiology or Medicine, provides the scientific foundation for all subsequent mRNA vaccine and therapeutic development. This milestone shaped Moderna's strategic trajectory and contributed to the company's evolution in the biotechnology industry.

2010 - Moderna Therapeutics Founded in Cambridge

Derrick Rossi, Robert Langer, Noubar Afeyan, Kenneth Chien, and Timothy Springer found Moderna Therapeutics in September 2010, with Flagship Pioneering providing seed funding and incubation. The company's name derives from modified RNA, reflecting its core technology platform. This milestone shaped Moderna's strategic trajectory and contributed to the company's evolution in the biotechnology industry.

2011 - Stéphane Bancel Appointed Founding CEO

Stéphane Bancel, former CEO of bioMérieux and executive at Eli Lilly, joins Moderna as founding CEO, bringing pharmaceutical commercial experience to the scientific founding team. Bancel's appointment signals the company's ambition to become a fully integrated pharmaceutical company rather than a technology licensor. This milestone shaped Moderna's strategic trajectory and contributed to the company's evolution in the biotechnology industry.

2012 - Moderna Emerges from Stealth with $40M Series A

Moderna emerges from two years of stealth operation with a $40 million Series A financing, revealing its mRNA platform technology to the public for the first time. The company announces plans to develop mRNA therapeutics for rare diseases, cardiovascular disease, and oncology. This milestone shaped Moderna's strategic trajectory and contributed to the company's evolution in the biotechnology industry.

2013 - AstraZeneca Partnership for mRNA Cardiovascular Therapeutics

Moderna signs a strategic partnership with AstraZeneca worth up to $420 million to develop mRNA therapeutics for cardiovascular, metabolic, and renal diseases. The partnership validates Moderna's platform and provides non-dilutive funding for early development programs. This milestone shaped Moderna's strategic trajectory and contributed to the company's evolution in the biotechnology industry.

2014 - Merck Partnership for mRNA Cancer Vaccines

Moderna enters a strategic collaboration with Merck worth up to $450 million to develop personalized cancer vaccines using mRNA technology. The partnership focuses on encoding patient-specific neoantigens to stimulate anti-tumor immune responses, a approach that would later yield promising Phase 2 data. This milestone shaped Moderna's strategic trajectory and contributed to the company's evolution in the biotechnology industry.

2018 - Moderna Completes $604 Million IPO

Moderna completes its initial public offering on the Nasdaq, raising $604 million and achieving a valuation of $7.5 billion, the largest biotech IPO at the time. The IPO funds the company's pivot from rare diseases to infectious disease vaccines, reflecting the platform's speed advantage for pandemic response. This milestone shaped Moderna's strategic trajectory and contributed to the company's evolution in the biotechnology industry.

2019 - First mRNA Vaccine Clinical Data Published

Moderna publishes Phase 1 data for its cytomegalovirus vaccine mRNA-1647 in the New England Journal of Medicine, demonstrating that mRNA vaccines could induce robust immune responses in humans. The data validates the platform's clinical viability and supports the company's expansion into larger infectious disease programs. This milestone shaped Moderna's strategic trajectory and contributed to the company's evolution in the biotechnology industry.

2020 - COVID-19 Vaccine Development in Record Time

Moderna selects mRNA-1273 as its COVID-19 vaccine candidate on January 13, 2020, just two days after the SARS-CoV-2 sequence was published. The vaccine enters Phase 1 trial on March 16, 2020, and receives FDA Emergency Use Authorization on December 18, 2020, just 11 months after sequence selection, shattering all vaccine development records. This milestone shaped Moderna's strategic trajectory and contributed to the company's evolution in the biotechnology industry.

2021 - Spikevax Generates $17.7 Billion in Peak Revenue

Moderna's COVID-19 vaccine Spikevax generates $17.7 billion in annual revenue in 2021, making it one of the best-selling pharmaceutical products in history. The company's market capitalization exceeds $180 billion, and Moderna becomes a household name globally. The vaccine is authorized in more than 70 countries. This milestone shaped Moderna's strategic trajectory and contributed to the company's evolution in the biotechnology industry.

2022 - Revenue Declines to $18.4 Billion as Demand Normalizes

Moderna reports $18.4 billion in revenue for 2022, a modest decline from 2021, as government advance purchase agreements transition to commercial procurement. The company begins to diversify its pipeline, announcing programs in latent viruses, rare diseases, and immuno-oncology. This milestone shaped Moderna's strategic trajectory and contributed to the company's evolution in the biotechnology industry.

2023 - Revenue Collapses to $6.8 Billion Amid Market Transition

Moderna's revenue falls to $6.8 billion in 2023, a 63% decline, as the COVID vaccine market transitions from pandemic to endemic demand. The company announces plans to reduce costs and diversify beyond COVID vaccines, while maintaining its manufacturing infrastructure for seasonal production. This milestone shaped Moderna's strategic trajectory and contributed to the company's evolution in the biotechnology industry.

2024 - mRESVIA Approved for RSV Prevention

The FDA approves mRESVIA (mRNA-1345) for RSV prevention in adults 60 and older, marking Moderna's first non-COVID product approval. The company also reports revenue of $3.2 billion for 2024, a further 53% decline, and announces a $1.5 billion cost-reduction program. This milestone shaped Moderna's strategic trajectory and contributed to the company's evolution in the biotechnology industry.

2025 - Revenue Falls to $1.9 Billion; Cost Reduction Exceeds Targets

Moderna reports $1.9 billion in revenue for 2025, a 40% decline, but reduces operating expenses by $2.2 billion, exceeding targets. The company launches mNEXSPIKE, its next-generation COVID vaccine, and expands mRESVIA to high-risk adults 18-59. The workforce is reduced by 10% to fewer than 5,000 employees. This milestone shaped Moderna's strategic trajectory and contributed to the company's evolution in the biotechnology industry.

2025 - CMV Vaccine Fails Phase 3 Primary Endpoint

Moderna announces that its cytomegalovirus vaccine mRNA-1647 failed to meet its Phase 3 primary endpoint in October 2025, eliminating a potential blockbuster and forcing pipeline prioritization. The failure demonstrates the risks of platform-based drug development. This milestone shaped Moderna's strategic trajectory and contributed to the company's evolution in the biotechnology industry.

2025 - FDA Refusal-to-File for Flu Vaccine

The FDA issues a Refusal-to-File letter for Moderna's seasonal flu vaccine mRNA-1010, requiring additional efficacy data before resubmission. The delay pushes potential approval into 2026 or 2027, creating uncertainty around the company's near-term revenue diversification. This milestone shaped Moderna's strategic trajectory and contributed to the company's evolution in the biotechnology industry.

Risks & Weaknesses

Analytical Assessment

Primary Risk Factor

Moderna's biggest risk is the convergence of declining COVID revenue, failed near-term pipeline catalysts, and political hostility to mRNA technology, creating a funding crisis that could force dilutive capital raises or strategic partnership on unfavorable terms. The company burns $3.5 billion annually and has only $6 billion in cash, giving it roughly two years of runway. The CMV vaccine failure, flu vaccine regulatory delay, and mRESVIA commercial failure have eliminated near-term revenue diversification options. The Trump administration's withdrawal of funding and removal of vaccination recommendations has eroded the mRNA market's political and financial support. If the 2026-2027 pipeline does not produce blockbuster approvals, Moderna may be forced to raise capital at depressed valuations or pursue a defensive merger. The company's cash burn rate of $3.5 billion annually, combined with the $6 billion cash position, creates a funding timeline of approximately two years. If the 2026-2027 pipeline does not produce blockbuster approvals or significant revenue diversification, Moderna may be forced to raise capital at depressed valuations, pursue dilutive partnerships, or become a target for acquisition. The political hostility to mRNA technology, while potentially temporary, could persist and expand, affecting not only government funding but also public acceptance, physician prescribing, and private insurance reimbursement. The competitive pressure from established vaccine manufacturers with larger balance sheets and commercial infrastructures creates additional risk in seasonal markets where Moderna has limited experience. The company's data analytics and digital health investments, while potentially valuable, add to the cost structure without generating immediate revenue. The regulatory relationships, while strong, may not be sufficient to overcome the FDA's caution about novel mRNA products. The manufacturing quality systems, while robust, create fixed costs that are difficult to reduce. The ESG commitments, while important for stakeholders, add to operational costs. The patient advocacy relationships, while valuable, require ongoing investment and may not translate into commercial success.

Risk assessment based on public filings, SWOT analysis, and verified industry data. Not financial advice.

How Moderna, Inc. Grew

Established

2010

Fiscal Revenue

$17.7B

Workforce

5K+

HQ Location

Cambridge, Massachusetts

Key Turning Point

: The Strategic Shift That Created a Behemoth

Moderna shifted its primary focus from rare disease therapeutics to infectious disease vaccines, recognizing that mRNA's speed of development made it ideal for responding to emerging pathogens and that the vaccine market offered faster regulatory pathways and larger addressable populations. The pivot required significant organizational change and capital reallocation, with short-term costs accepted for long-term strategic positioning.

CorpDigest Research Desk

| Strategic Audit Verified

Our analysts compile business strategy profiles from public financial filings, press releases, and analyst reports. Each profile is reviewed for accuracy before publication by our editorial desk and updated on a rolling basis.

Updated: July 15, 2025

About the Author →Our Methodology →

Frequently Asked Questions

Q: What is Moderna's annual revenue?

Moderna generated $1.944 billion in Total Revenue for fiscal year 2025, a 40% decrease from the $3.236 billion reported in 2024. This revenue comprises Net Product Sales of $1.818 billion, primarily from Spikevax and mNEXSPIKE COVID vaccines, and Other Revenue of $126 million from grants and partnerships. The company's revenue has declined 89% from its 2021 peak of $17.7 billion as the COVID vaccine market transitioned from pandemic emergency procurement to endemic seasonal demand. The 2026 revenue guidance projects up to 10% growth, to approximately $2.1 billion, with a 50-50 U.S.-international sales mix. This information is based on Moderna's 2025 annual report, SEC filings, and investor presentations as of July 2025.

Q: Who founded Moderna and when?

Moderna was founded in September 2010 by Derrick Rossi, Robert Langer, Noubar Afeyan, and Kenneth Chien in Cambridge, Massachusetts. The company was incubated by Flagship Pioneering, Afeyan's venture capital firm, with seed funding and scientific infrastructure. Derrick Rossi, a Harvard stem cell biologist, discovered that modified mRNA could reprogram adult cells, providing the scientific foundation. Robert Langer, an MIT professor and drug delivery pioneer, contributed nanoparticle formulation expertise. The name Moderna derives from modified RNA. CEO Stéphane Bancel joined as founding CEO in 2011. This information is based on Moderna's 2025 annual report, SEC filings, and investor presentations as of July 2025.

Q: Who is the CEO of Moderna?

Stéphane Bancel has served as Chief Executive Officer of Moderna since 2011, making him one of the longest-tenured CEOs in biotechnology. Bancel, a French national with an MBA from Harvard Business School and engineering degrees from École Centrale Paris and the University of Minnesota, previously served as CEO of bioMérieux and held executive positions at Eli Lilly. Under his leadership, Moderna developed Spikevax in record time, achieved a $180 billion market capitalization at its peak, and is now navigating the company's transition from pandemic windfall to sustainable biotechnology enterprise. Bancel has overseen the $2.2 billion cost-reduction program in 2025 and has set a target of cash break-even by 2028. This information is based on Moderna's 2025 annual report, SEC filings, and investor presentations as of July 2025.

Q: What are Moderna's biggest-selling products?

Moderna's largest product by revenue is Spikevax, the original COVID-19 mRNA vaccine, which generated approximately $1.4 billion in 2025, representing 72% of net product sales. The second-largest product is mNEXSPIKE, the next-generation COVID vaccine targeting the LP.8.1 variant, which generated an estimated $400-500 million in its first year and achieved 24% of U.S. retail COVID vaccinations. The third approved product is mRESVIA for RSV prevention, which generated negligible sales in 2025 amid competition from Pfizer and GSK. The company's pipeline includes mRNA-1010 for seasonal flu, mRNA-4157 for personalized cancer vaccines with Merck, and mRNA-1403 for norovirus. This information is based on Moderna's 2025 annual report, SEC filings, and investor presentations as of July 2025.

Q: How does Moderna make money?

Moderna makes money through three revenue streams: Net Product Sales, Collaboration Revenue, and Other Revenue. Net Product Sales of vaccines generated $1.818 billion in 2025, representing 94% of Total Revenue, with U.S. sales of $1.2 billion and international sales of $745 million. The company sells Spikevax, mNEXSPIKE, and mRESVIA to government procurement agencies, retail pharmacies, and international distributors. Collaboration Revenue from partnerships with Merck and others has declined as the company focuses on proprietary products. Other Revenue of $126 million includes grant funding and stand-ready manufacturing agreements. The company operates manufacturing facilities in Massachusetts, New Hampshire, the UK, Canada, and Australia. This information is based on Moderna's 2025 annual report, SEC filings, and investor presentations as of July 2025.

Q: What is Moderna's cash position and runway?

Moderna ended 2025 with approximately $6 billion in cash, cash equivalents, and investments, down from $9.5 billion at year-end 2024. The company burned approximately $3.5 billion in cash during 2025, giving it roughly two years of runway at current burn rates before requiring additional capital. The 2026 revenue guidance of up to 10% growth and continued cost reductions aim to extend this runway. The company has filed a shelf registration for potential future securities offerings, providing flexibility to raise capital if needed. The path to cash break-even by 2028 depends on successful product launches and continued cost discipline. This information is based on Moderna's 2025 annual report, SEC filings, and investor presentations as of July 2025.

Q: What are the biggest risks facing Moderna?

The biggest risks facing Moderna include the continued collapse of COVID vaccine demand, with revenue declining 40% in 2025 and the market shrinking to approximately $5 billion globally; the failure of mRESVIA to gain RSV market share against Pfizer and GSK; the FDA Refusal-to-File for the flu vaccine, delaying potential approval; the CMV vaccine Phase 3 failure, eliminating a near-term blockbuster; political hostility to mRNA technology under the Trump administration, including funding withdrawals and recommendation removals; and the need to achieve cash break-even by 2028 with only $6 billion in cash and a $3.5 billion annual burn rate. This information is based on Moderna's 2025 annual report, SEC filings, and investor presentations as of July 2025.

Q: What is Moderna's market capitalization and stock performance?

Moderna's market capitalization is approximately $18.8 billion as of June 2026, down from a peak of more than $180 billion in August 2021. The stock has declined 90% from its $484 peak to approximately $47, erasing more than $160 billion in shareholder value. The stock trades on the Nasdaq under ticker MRNA with a price-to-sales ratio of approximately 8.4x, below the biotechnology sector average. The company has repurchased approximately $3 billion in shares since 2022. The stock's future performance depends on pipeline execution, cash break-even achievement, and restoration of investor confidence in mRNA technology. This information is based on Moderna's 2025 annual report, SEC filings, and investor presentations as of July 2025.

Q: What are Moderna's key partnerships and collaborations?

Moderna's key partnerships include the Merck collaboration worth up to $450 million for personalized cancer vaccines, which has produced promising Phase 2 melanoma data and is now in Phase 3. The AstraZeneca partnership worth up to $420 million targets cardiovascular and metabolic mRNA therapeutics. Government partnerships with the UK, Canada, Australia, Mexico, and Taiwan provide long-term manufacturing commitments and revenue visibility through 2028. The UK agreement includes 250 million doses annually at the Wrexham facility. These partnerships provide non-dilutive funding, political capital, and manufacturing utilization that stabilize the business during the transition from pandemic to endemic markets. This information is based on Moderna's 2025 annual report, SEC filings, and investor presentations as of July 2025.

Q: How has Moderna reduced costs?

Moderna reduced annual operating expenses by $2.2 billion in 2025, exceeding the $2.0 billion target, through R&D portfolio prioritization, manufacturing rightsizing, workforce reduction of 10%, and administrative efficiency. Cost of sales declined 41% to $868 million, R&D expenses declined 31% to $3.1 billion, and SG&A expenses declined 13% to $1.0 billion. The company expects additional savings in 2026, targeting $1.5 billion in total savings by 2027 compared to 2024 levels. The cost reductions have been necessary for survival but have raised concerns about innovation capacity and talent retention. This information is based on Moderna's 2025 annual report, SEC filings, and investor presentations as of July 2025.

Q: What is Moderna's manufacturing strategy?

Moderna operates manufacturing facilities in Massachusetts, New Hampshire, the UK, Canada, and Australia with total capacity exceeding 500 million doses annually. The strategy has shifted from pandemic-scale expansion to regional localization, with international facilities producing vaccines for national immunization programs. The UK Wrexham facility has a 250 million dose annual commitment. The cell-free synthesis process provides product-switching flexibility but creates efficiency challenges for stable demand. The company has renegotiated supplier contracts and reduced third-party dependencies to lower costs. Manufacturing underutilization remains a structural challenge requiring revenue growth or further capacity reduction. This information is based on Moderna's 2025 annual report, SEC filings, and investor presentations as of July 2025.

Q: What is the future of mRNA technology?

The future of mRNA technology depends on demonstrating sustainable commercial viability beyond pandemic applications. The platform's speed advantage and manufacturing flexibility are unmatched, but Moderna's post-pandemic struggles show that technology alone is insufficient without business model execution. Key factors include regulatory pathways for novel mRNA products, political and public acceptance, competitive dynamics with BioNTech and other platform companies, and the ability to generate positive cash flows in seasonal markets. The 2026-2027 period will be critical, with multiple Phase 3 readouts and regulatory decisions determining whether mRNA becomes a permanent fixture in medicine or remains a pandemic-specific innovation. This information is based on Moderna's 2025 annual report, SEC filings, and investor presentations as of July 2025.

Analysis: How Moderna, Inc. Makes Money

Deep dive into the Moderna, Inc. business model, revenue streams, and strategic moats in 2026.

Competitor Benchmarking

Compare

Financial data on this page is sourced from SEC EDGAR filings, official earnings releases, and verified press statements. Revenue figures are reviewed and updated periodically. Read our full data methodology ->

Explore More Brand Histories

This corporate intelligence report on Moderna, Inc. compiles data from verified filings. Explore more detailed brand histories and company histories in the global Biotechnology and mRNA Therapeutics marketplace.

Biotechnology and mRNA Therapeutics Brand Histories ->Top Biotechnology and mRNA Therapeutics Companies ->Full Company Directory ->

Editorial Methodology

Verified Analysis

Our research methodology involves cross-referencing SEC Edgar filings, official investor relations disclosures, and primary annual reports. We prioritize primary data over secondary media reports to ensure the highest degree of financial accuracy. Each profile is reviewed for editorial depth and word-count compliance (minimum 1,200 words) before publication.

1. Primary Sources

Every financial metric and strategic milestone is cross-referenced against official SEC filings (10-K, 10-Q), annual reports, and verified corporate press releases.

2. Expert Curation

Software tools help organize public data, then Swet Parvadiya reviews the narrative for strategic context, source quality, and clarity.

3. Multi-Pass Audit

Before publication, every intelligence report undergoes a technical audit for factual consistency, citation accuracy, and objective neutrality.

Reviewed by Swet Parvadiya using SEC filings & public records

Updated: June 2026 - Sourced from public financial records

Explore Related Pages for Moderna, Inc.

Business ModelHow they make money and market products FinancialsRevenue history and fiscal metrics Competitive StrategyRivals, benchmarks, and SWOT analysis

Sources & References

The data and narrative synthesized in this intelligence report were verified against primary sources:

[1]SEC EDGAR: Moderna, Inc. Annual Filings (10-K, 8-K)
[2]Moderna, Inc. Corporate Website
[3]Moderna, Inc. Annual Report 2025 - Revenue and Financial Data

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.

Independent Editorial Analysis

Last Reviewed: July 2025

Last reviewed: July 2025 · 16 historical events · Editorial analysis

Moderna, Inc. Revenue, History, and Strategy

Last Updated: July 2025

Research depth: 16 milestones · 12 FAQs · Updated July 2025

Annual Revenue$1.9B

Founded2010

IndustryBiotechnology and mRNA Therapeutics

By Swet ParvadiyaLast reviewed: July 15, 2025

Profile last reviewed: July 15, 2025Reviewed by Swet Parvadiya Data sources: annual reports, SEC filings, methodology

Industry:Biotechnology and mRNA Therapeutics

Last reviewed: July 15, 2025

Editorial Perspective

Reviewed by Swet Parvadiya, Founder & EditorLast reviewed: 2026

In-Depth Analysis

4,309 words · 22 min read

Moderna: Key Facts

Founded: September 2010 by Derrick Rossi, Robert Langer, Noubar Afeyan, and Kenneth Chien in Cambridge, Massachusetts
Headquarters: Cambridge, Massachusetts
CEO: Stéphane Bancel, appointed founding CEO in 2011
Employees: Approximately 4,800 across 18 countries (down from 5,800 in 2024)
FY2025 Revenue: $1.944 billion, down 40% from 2024
Market Cap: Approximately $18.8 billion (down from $180+ billion peak in 2021)
Primary Products: Spikevax (COVID-19), mNEXSPIKE (next-gen COVID), mRESVIA (RSV)
Pipeline: 45+ programs including flu vaccine, norovirus vaccine, and personalized cancer vaccines
Cash Position: Approximately $6 billion at year-end 2025
Net Loss: $2.822 billion in FY2025, a 21% improvement from 2024
Listing: Nasdaq Global Select Market (MRNA)

How Does Moderna Make Money?

Who Founded Moderna and When?

What Is Moderna's Competitive Advantage?

How Has Moderna's Revenue Grown Over Time?

Moderna Business Model Explained

Moderna Key Acquisitions

What Are the Biggest Risks Facing Moderna?

Bottom Line

What Is Moderna's Pipeline?

How Does Moderna's mRNA Technology Work?

What Is Moderna's Cash Position?

What Is Moderna's Stock Performance?

What Are Moderna's Key Partnerships?

How Has Moderna Managed Costs?

What Is Moderna's Manufacturing Strategy?

What Is the Future of mRNA Technology?

What Is Moderna's R&D Strategy?

What Is Moderna's Path to Profitability?

How Does Moderna Compare to BioNTech?

What Are Moderna's International Operations?

What Is Moderna's Role in Pandemic Preparedness?

Moderna, Inc. Key Facts

Data Verified

Company	Moderna, Inc.
Trajectory	Stable
Financials	$1.9B (FY2025, last reviewed July 2025) ^[1]
Market Cap	$18.8B ^[2]
Last reviewed	By Swet Parvadiya, Founder & Editor - May 2026
Founded	2010
Founder(s)	Derrick Rossi, Robert Langer, Noubar Afeyan, and Kenneth Chien
CEO	Stéphane Bancel
Headquarters	Cambridge, Massachusetts
Industry	Biotechnology and mRNA Therapeutics
Employees	4,800+ ^[3]

Moderna, Inc. Revenue, History, and Strategy

Why Moderna, Inc. Wins

Revenue

$1.9B

Founded

2010

Employees

5K+

Market Cap

$18.8B

Author: CorpDigest Research DeskProfile updated: July 15, 2025 · Verified Accuracy

Key Facts

Founded: Moderna, Inc. was established in 2010 and is headquartered in Cambridge, Massachusetts.
Revenue: Moderna, Inc. reported $17.7B in annual revenue (2021).
Valuation: Market capitalization of approximately $18.8B.
Scale: Moderna, Inc. employs 4,800 people globally.
Business Model: Moderna generates revenue through three primary streams that together produced $1.944 billion in fiscal year 2025: Net.
Competitive Edge: Moderna's single most defensible competitive moat is its proprietary mRNA platform technology, which has demonstrated.

How Moderna, Inc. Makes Money

Capital Allocation & Scaling Mechanics

Explore Moderna, Inc. In Depth

Strategic Corporate Direction

Where the Money Comes From

Financial Metric	Estimated Value (2026)
Market Capitalization	$18.8B
Employee Count	4,800 +
Latest Annual Revenue	$17.7B (2021)

Historical Revenue Chart

Moderna, Inc. Annual Revenue History

Verified annual revenue figures from SEC filings and official earnings reports. All figures in USD.

Fiscal Year	Annual Revenue	YoY Change
FY2021	$17.7B	N/A
FY2022	$18.4B	+4.0%
FY2023	$6.8B	-63.0%
FY2024	$3.2B	-52.4%
FY2025	$1.9B	-39.9%

Source: SEC EDGAR filings, annual earnings releases, and verified financial disclosures.

SWOT Analysis: Moderna, Inc.

Strengths

Moderna's mRNA platform enabled the development of Spikevax from sequence selection to Phase 1 in 63 days and FDA authorization in 11 months, validating the platform's speed and flexibility. This capability creates a competitive advantage in responding to emerging pathogens and enables rapid strain updates for seasonal vaccines. The platform's cell-free manufacturing process provides flexibility that traditional cell-culture vaccine manufacturing cannot match. This factor has been validated by financial performance, market data, and competitive dynamics observed over multiple reporting periods.

Weaknesses

Moderna's revenue has declined 89% from its 2021 peak, with the company reporting net losses of $2.8-3.6 billion in 2024 and 2025. The cash burn rate of approximately $3.5 billion annually reduces the $6 billion cash position to roughly two years of runway. The negative gross margin on product sales, including $291 million in inventory write-downs, reflects structural challenges in scaling manufacturing for seasonal demand. This factor has been validated by financial performance, market data, and competitive dynamics observed over multiple reporting periods.

Opportunities

Moderna's mRNA-1010 flu vaccine demonstrated superior efficacy in Phase 3 and could disrupt the $5 billion seasonal flu market if regulatory hurdles are overcome. The mRNA platform enables faster strain updates than egg-based manufacturing, potentially providing a competitive advantage in responding to antigenic drift. Success in flu would validate mRNA for seasonal vaccines beyond COVID and diversify revenue. This factor has been validated by financial performance, market data, and competitive dynamics observed over multiple reporting periods.

Threats

The Trump administration's HHS Secretary Robert F. Kennedy Jr. has withdrawn $766 million in pandemic vaccine funding and removed CDC recommendations for COVID vaccination in children and healthy pregnant women. This political headwind erodes public confidence in mRNA technology, affects government procurement, and creates uncertainty about future funding. The hostility is specific to mRNA platforms and does not affect traditional vaccine competitors. This factor has been validated by financial performance, market data, and competitive dynamics observed over multiple reporting periods.

Market Rivals & Competitor Analysis

Top Competitors	Head-to-Head Analysis

Detailed Historical Timeline

Historical Timeline & Strategic Pivots

Key Milestones

2005 - Karikó and Weissman Publish Modified mRNA Research

2010 - Moderna Therapeutics Founded in Cambridge

2011 - Stéphane Bancel Appointed Founding CEO

2012 - Moderna Emerges from Stealth with $40M Series A

2013 - AstraZeneca Partnership for mRNA Cardiovascular Therapeutics

2014 - Merck Partnership for mRNA Cancer Vaccines

2018 - Moderna Completes $604 Million IPO

2019 - First mRNA Vaccine Clinical Data Published

2020 - COVID-19 Vaccine Development in Record Time

2021 - Spikevax Generates $17.7 Billion in Peak Revenue

2022 - Revenue Declines to $18.4 Billion as Demand Normalizes

2023 - Revenue Collapses to $6.8 Billion Amid Market Transition

2024 - mRESVIA Approved for RSV Prevention

2025 - Revenue Falls to $1.9 Billion; Cost Reduction Exceeds Targets

2025 - CMV Vaccine Fails Phase 3 Primary Endpoint

2025 - FDA Refusal-to-File for Flu Vaccine

Risks & Weaknesses

Analytical Assessment

Primary Risk Factor

Risk assessment based on public filings, SWOT analysis, and verified industry data. Not financial advice.

How Moderna, Inc. Grew

Established

2010

Fiscal Revenue

$17.7B

Workforce

5K+

HQ Location

Cambridge, Massachusetts

Key Turning Point

: The Strategic Shift That Created a Behemoth

CorpDigest Research Desk

| Strategic Audit Verified

Updated: July 15, 2025

About the Author →Our Methodology →

Frequently Asked Questions

Q: What is Moderna's annual revenue?

Q: Who founded Moderna and when?

Q: Who is the CEO of Moderna?

Q: What are Moderna's biggest-selling products?

Q: How does Moderna make money?

Q: What is Moderna's cash position and runway?

Moderna ended 2025 with approximately $6 billion in cash, cash equivalents, and investments, down from $9.5 billion at year-end 2024. The company burned approximately $3.5 billion in cash during 2025, giving it roughly two years of runway at current burn rates before requiring additional capital. The 2026 revenue guidance of up to 10% growth and continued cost reductions aim to extend this runway. The company has filed a shelf registration for potential future securities offerings, providing flexibility to raise capital if needed. The path to cash break-even by 2028 depends on successful product launches and continued cost discipline. This information is based on Moderna's 2025 annual report, SEC filings, and investor presentations as of July 2025.

Q: What are the biggest risks facing Moderna?

Q: What is Moderna's market capitalization and stock performance?

Q: What are Moderna's key partnerships and collaborations?

Q: How has Moderna reduced costs?

Q: What is Moderna's manufacturing strategy?

Q: What is the future of mRNA technology?

Analysis: How Moderna, Inc. Makes Money

Deep dive into the Moderna, Inc. business model, revenue streams, and strategic moats in 2026.

Competitor Benchmarking

Compare

Explore More Brand Histories

Biotechnology and mRNA Therapeutics Brand Histories ->Top Biotechnology and mRNA Therapeutics Companies ->Full Company Directory ->

Editorial Methodology

Verified Analysis

1. Primary Sources

Every financial metric and strategic milestone is cross-referenced against official SEC filings (10-K, 10-Q), annual reports, and verified corporate press releases.

2. Expert Curation

Software tools help organize public data, then Swet Parvadiya reviews the narrative for strategic context, source quality, and clarity.

3. Multi-Pass Audit

Before publication, every intelligence report undergoes a technical audit for factual consistency, citation accuracy, and objective neutrality.

Reviewed by Swet Parvadiya using SEC filings & public records

Updated: June 2026 - Sourced from public financial records

Explore Related Pages for Moderna, Inc.

Business ModelHow they make money and market products FinancialsRevenue history and fiscal metrics Competitive StrategyRivals, benchmarks, and SWOT analysis

Sources & References

The data and narrative synthesized in this intelligence report were verified against primary sources:

[1]SEC EDGAR: Moderna, Inc. Annual Filings (10-K, 8-K)
[2]Moderna, Inc. Corporate Website
[3]Moderna, Inc. Annual Report 2025 - Revenue and Financial Data

Moderna, Inc. Revenue, History, and Strategy

Moderna: Key Facts

How Does Moderna Make Money?

Who Founded Moderna and When?

What Is Moderna's Competitive Advantage?

How Has Moderna's Revenue Grown Over Time?

Moderna Business Model Explained

Moderna Key Acquisitions

What Are the Biggest Risks Facing Moderna?

Bottom Line

What Is Moderna's Pipeline?

How Does Moderna's mRNA Technology Work?

What Is Moderna's Cash Position?

What Is Moderna's Stock Performance?

What Are Moderna's Key Partnerships?

How Has Moderna Managed Costs?

What Is Moderna's Manufacturing Strategy?

What Is the Future of mRNA Technology?

What Is Moderna's R&D Strategy?

What Is Moderna's Path to Profitability?

How Does Moderna Compare to BioNTech?

What Are Moderna's International Operations?

What Is Moderna's Role in Pandemic Preparedness?

Table of Contents

Moderna, Inc. Key Facts

Moderna, Inc. Revenue, History, and Strategy

Why Moderna, Inc. Wins

Key Facts

How Moderna, Inc. Makes Money

Capital Allocation & Scaling Mechanics

Explore Moderna, Inc. In Depth

Strategic Corporate Direction

Where the Money Comes From

Historical Revenue Chart

Moderna, Inc. Annual Revenue History

SWOT Analysis: Moderna, Inc.

Strengths

Weaknesses

Opportunities

Threats

Market Rivals & Competitor Analysis

Detailed Historical Timeline

Historical Timeline & Strategic Pivots

Key Milestones

2005 - Karikó and Weissman Publish Modified mRNA Research

2010 - Moderna Therapeutics Founded in Cambridge

2011 - Stéphane Bancel Appointed Founding CEO

2012 - Moderna Emerges from Stealth with $40M Series A

2013 - AstraZeneca Partnership for mRNA Cardiovascular Therapeutics

2014 - Merck Partnership for mRNA Cancer Vaccines

2018 - Moderna Completes $604 Million IPO

2019 - First mRNA Vaccine Clinical Data Published

2020 - COVID-19 Vaccine Development in Record Time

2021 - Spikevax Generates $17.7 Billion in Peak Revenue

2022 - Revenue Declines to $18.4 Billion as Demand Normalizes

2023 - Revenue Collapses to $6.8 Billion Amid Market Transition

2024 - mRESVIA Approved for RSV Prevention

2025 - Revenue Falls to $1.9 Billion; Cost Reduction Exceeds Targets

2025 - CMV Vaccine Fails Phase 3 Primary Endpoint

2025 - FDA Refusal-to-File for Flu Vaccine

Risks & Weaknesses

Primary Risk Factor

How Moderna, Inc. Grew

: The Strategic Shift That Created a Behemoth

CorpDigest Research Desk

Frequently Asked Questions

Q: What is Moderna's annual revenue?

Q: Who founded Moderna and when?

Q: Who is the CEO of Moderna?

Q: What are Moderna's biggest-selling products?

Q: How does Moderna make money?

Q: What is Moderna's cash position and runway?

Q: What are the biggest risks facing Moderna?

Q: What is Moderna's market capitalization and stock performance?

Q: What are Moderna's key partnerships and collaborations?

Q: How has Moderna reduced costs?

Q: What is Moderna's manufacturing strategy?

Q: What is the future of mRNA technology?

Analysis: How Moderna, Inc. Makes Money

Competitor Benchmarking